Top

Published in:

Open Access 01-12-2019 | Cannabinoid | Protocol

Clinical applications of palmitoylethanolamide in pain management: protocol for a scoping review

Authors: Maria Beatrice Passavanti, Aniello Alfieri, Maria Caterina Pace, Vincenzo Pota, Pasquale Sansone, Giacomo Piccinno, Manlio Barbarisi, Caterina Aurilio, Marco Fiore

Published in: Systematic Reviews | Issue 1/2019

Abstract

Background

Palmitoylethanolamide (PEA) belong to endocannabinoid family, a group of fatty acid amides. PEA has been proven to have analgesic and anti-inflammatory activity and has been used in several controlled studies focused on the management of chronic pain among adult patients with different underlying clinical conditions.

Methods/design

A literature search will be performed using PubMed, EMBASE, and the Cochrane Central Register of Controlled Trials (CENTRAL). The population will be patients who have chronic pain, the intervention will be the administration of PEA alone or in combination with other drugs for the pain management; the comparison will be the standard therapy in accordance with the current guidelines for the treatment of pain. The Outcomes will be the reduction of pain not restricted to specific scales laying out the pain outcome data described in the included studies.

Discussion

This scoping review aims to describe the clinical applications of the PEA in chronic pain management and its outcome.

Scoping review registration

Open Science Framework https://osf.io/74tmx/.

Hansen HS. Palmitoylethanolamide and other anandamide congeners. Proposed role in the diseased brain. Exp Neurol. 2010;224(1):48–55 https://doi.org/10.1016/j.expneurol.2010.03.022.CrossRef

Petrosino S, Iuvone T, Di Marzo V. N-palmitoyl-ethanolamine: biochemistry and new therapeutic opportunities. Biochimie. 2010;92(6):724–7 https://doi.org/10.1016/j.biochi.2010.01.006.CrossRef

Cerrato S, Brazis P, della Valle MF, Miolo A, Puigdemont A. Effects of palmitoylethanolamide on immunologically induced histamine, PGD2 and TNFα release from canine skin mast cells. Vet Immunol Immunopathol. 2010;133(1):9–15 https://doi.org/10.1016/j.vetimm.2009.06.011.CrossRef

Costa B, Colombo A, Bettoni I, Bresciani E, Torsello A, Comelli F. The endogenous ligand palmitoylethanolamide relieves neuropathic pain via mast cell and microglia modulation. 21st Annual Symposium Of The International Cannabinoid Research Society. St. Charles, Il. Usa: Pheasant Run; 2011. http://icrs.co/SYMPOSIUM.2011/ICRS2011.Final.Programme.pdf.

Genovese T, Esposito E, Mazzon E, Di Paola R, Meli R, Bramanti P, Piomelli D, Calignano A, Cuzzocrea S. Effects of palmitoylethanolamide on signaling pathways implicated in the development of spinal cord injury. J Pharmacol Exp Ther. 2008;326(1):12–23. https://doi.org/10.1124/jpet.108.136903.CrossRef

Esposito E, Paterniti I, Mazzon E, Genovese T, Di Paola R, Galuppo M, Cuzzocrea S. Effects of palmitoylethanolamide on release of mast cell peptidases and neurotrophic factors after spinal cord injury. Brain Behav Immun. 2011;25(6):1099–112 https://doi.org/10.1016/j.bbi.2011.02.006.CrossRef

Facci L, Dal Toso R, Romanello S, Buriani A, Skaper SD, Leon A. Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc Natl Acad Sci U S A. 1995;92(8):3376–80 7724569.CrossRef

Sugiura T, Kondo S, Kishimoto S, Miyashita T, Nakane S, Kodaka T, Suhara Y, Takayama H, Waku K. Evidence that 2-arachidonoylglycerol but not N-palmitoylethanolamine or anandamide is the physiological ligand for the cannabinoid CB2 receptor. Comparison of the agonistic activities of various cannabinoid receptor ligands in HL-60 cells. J Biol Chem. 2000;275(1):605–12 https://doi.org/10.1074/jbc.275.1.605January 7, 2000.CrossRef

Costa B, Conti S, Giagnoni G, Colleoni M. Therapeutic effect of the endogenous fatty acid amide, palmitoylethanolamide, in rat acute inflammation: inhibition of nitric oxide and cyclo-oxygenase systems. Br J Pharmacol. 2002;137(4):413–20. https://doi.org/10.1038/sj.bjp.0704900.CrossRef

10.

Petrosino S, Di Marzo V. The pharmacology of palmitoylethanolamide and first data on the therapeutic efficacy of some of its new formulations. Br J Pharmacol. 2017;174(11):1349–65. https://doi.org/10.1111/bph.13580.CrossRef

11.

Di Marzo V, Melck D, Orlando P, Bisogno T, Zagoory O, Bifulco M, Vogel Z, De Petrocellis L. Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide in human breast cancer cells. Biochem J. 2001;358(Pt 1):249–55 11485574.CrossRef

12.

Passavanti MB, Fiore M, Sansone P, Aurilio C, Pota V, Barbarisi M, Fierro D, Pace MC. The beneficial use of ultramicronized palmitoylethanolamide as add-on therapy to Tapentadol in the treatment of low back pain: a pilot study comparing prospective and retrospective observational arms. BMC Anesthesiol. 2017;17(1):171. https://doi.org/10.1186/s12871-017-0461-9.CrossRef

13.

Germini F, Coerezza A, Andreinetti L, Nobili A, Rossi PD, Mari D, Guyatt G, Marcucci M. N-of-1 randomized trials of ultra-micronized palmitoylethanolamide in older patients with chronic pain. Drugs Aging. 2017;34(12):941–52 https://doi.org/10.1007/s40266-017-0506-2.CrossRef

14.

Chirchiglia D, Chirchiglia P, Signorelli F. Nonsurgical lumbar radiculopathies treated with ultramicronized palmitoylethanolamide (umPEA): a series of 100 cases. Neurol Neurochir Pol. 2018;52(1):44–7. https://doi.org/10.1016/j.pjnns.2017.11.002.PubMed

15.

Giammusso B, Di Mauro R, Bernardini R. The efficacy of an association of palmitoylethanolamide and alpha-lipoic acid in patients with chronic prostatitis/chronic pelvic pain syndrome: a randomized clinical trial. Arch Ital Urol Androl. 2017;89(1):17–21.CrossRef

16.

Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, Moher D, Peters MDJ, Horsley T, Weeks L, Hempel S, Akl EA, Chang C, McGowan J, Stewart L, Hartling L, Aldcroft A, Wilson MG, Garritty C, Lewin S, Godfrey CM, Macdonald MT, Langlois EV, Soares-Weiser K, Moriarty J, Clifford T, Tunçalp Ö, Straus SE. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med. 2018;169(7):467–73 https://doi.org/10.7326/M18-0850.CrossRef

Title: Clinical applications of palmitoylethanolamide in pain management: protocol for a scoping review
Authors: Maria Beatrice Passavanti
Aniello Alfieri
Maria Caterina Pace
Vincenzo Pota
Pasquale Sansone
Giacomo Piccinno
Manlio Barbarisi
Caterina Aurilio
Marco Fiore
Publication date: 01-12-2019
Publisher: BioMed Central
Keyword: Cannabinoid
Published in: Systematic Reviews / Issue 1/2019
Electronic ISSN: 2046-4053
DOI: https://doi.org/10.1186/s13643-018-0934-z

At a glance: The STEP trials

Springer Medicine

Clinical applications of palmitoylethanolamide in pain management: protocol for a scoping review

Abstract

Background

Methods/design

Discussion

Scoping review registration

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods/design

Discussion

Scoping review registration

Please log in to get access to this content

Other articles of this Issue 1/2019

Antiviral treatment for treatment-naïve chronic hepatitis B: systematic review and network meta-analysis of randomized controlled trials

Defining the concept of family caregiver burden in patients with schizophrenia: a systematic review protocol

Effects of physical exercise on outcomes of cardiac (dys)function in women with breast cancer undergoing anthracycline or trastuzumab treatment: study protocol for a systematic review

Correction to: The macro-economic determinants of health and health inequalities—umbrella review protocol

Mapping evidence on tuberculosis active case finding policies, strategies, and interventions for tuberculosis key populations: a systematic scoping review protocol

Does testosterone mediate the relationship between vitamin D and prostate cancer? A systematic review and meta-analysis protocol